Monitor for any follow-up disclosures on committee assignments or strategic input from the new director, but expect minimal near-term impact on operations or valuation given the routine nature of this board transition.
RYTM drugs
RYTM drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 6 $86.96entry
- T+1 · 7mo ago −0.34%α −0.41% · $86.66
- T+5 · 7mo ago −0.17%α −4.31% · $86.81
- T+20 · 7mo ago −1.59%α −10.57% · $85.58
- T+60 · 5mo ago +26.97%α +13.50% · $110.41
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Rhythm Pharmaceuticals announced the appointment of Kimberly Popovits to its Board of Directors and the resignation of Edward T. Mathers, effective April 1, 2026. The changes reflect a routine board transition, with Popovits bringing extensive biopharma leadership experience and Mathers departing amicably after years of service.
Key Facts
- Kimberly J. Popovits appointed to the Board of Directors effective April 1, 2026, as a Class II director
- Edward T. Mathers resigned from the Board effective April 1, 2026, with no disagreement with the company
- Popovits has prior leadership experience as CEO of Genomic Health and senior roles at Genentech
- No financial terms, compensation changes, or strategic shifts were disclosed in connection with the board changes
Financial Impact
No direct financial impact disclosed
Risk Factors
- Potential shift in board dynamics or strategic oversight over time with new director
- Loss of long-tenured director's institutional knowledge, though departure was amicable
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-023606 |
| Document: 0001628280-26-023606-index.html | 0001628280-26-023606 |
| Document: 0001628280-26-023606.txt | 0001628280-26-023606 |
Track record
26 reports on RYTM
9 of 14 bullish or bearish reports moved the stock their way by T+5. Best: +32.06% at T+60 after the May 1, 2026 report. 11 of 14 went positive at some point.
Filters
- Nov 16, 2026today Press Release Bullish 5/10 Entry $107.48 Now $107.48 +0.00% settles Nov 24
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
- Nov 4, 202612d ago Press Release Bullish 5/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
- Nov 3, 202613d ago 8-K Bullish 6/10 No price data
- Nov 3, 202613d ago Press Release Bullish 6/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
- Nov 2, 202614d ago Press Release Neutral 5/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
- Oct 13, 20264w ago Press Release Bullish 6/10 Entry $86.71 to $88.62 Now $107.48 +23.95% ▲ +2.20% +1.75% vs SPY
- Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $86.61 to $90.20 Now $107.48 +24.10% ▲ +4.14% +5.30% vs SPY
- Sep 14, 20269w ago 144 Bearish 5/10 Entry $96.77 to $99.27 Now $107.48 −11.07% ▼ −2.58% −0.47% vs SPY
- Aug 17, 202613w ago Insider Cluster Bearish 6/10 Entry $115.25 to $113.35 Now $107.48 +6.74% ▲ +1.65% +1.45% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers